Dear Doctor Letter (Rote-Hand-Brief) on Invirase® (saquinavir): Important new safety information on ECG monitoring
2014.05.28
Active substance: saquinavir
The company Roche Pharma AG is circulating information on new recommendations regarding ECG monitoring in treatment-naïve patients receiving Invirase® (saquinavir). This Dear Doctor Letter is intended to emphasise the necessity of ECG monitoring after beginning treatment with saquinavir/ritonavir as well as the recommended times for these controls.
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN